Poulvac E. coli

RSS

Poulvac E. coli lyophilisate for suspension for spray vaccination for chickens and turkeys or for use in drinking water for chickens

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European Public Assessment Report (EPAR) for Poulvac E. coli. It explains how the Agency assessed this veterinary medicine to recommend its authorisation in the European Union (EU) and its conditions of use.

For practical information about using Poulvac E. coli animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.

This EPAR was last updated on 09/11/2018

Authorisation details

Product details
Name
Poulvac E. coli
Agency product number
EMEA/V/C/002007
Active substance
Live aroA gene deleted Escherichia coli, type 078, strain EC34195
International non-proprietary name (INN) or common name
Poulvac E. coli lyophilisate for suspension for spray vaccination for chickens and turkeys or for use in drinking water for chickens
Species
  • Chicken
  • Turkeys
Anatomical therapeutic chemical veterinary (ATCvet) codes
QI01AE04
Publication details
Marketing-authorisation holder
Zoetis Belgium SA
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
15/06/2012
Contact address
Rue Laid Burnait, 1
1348 Louvain-la-Neuve
Belgium

Product information

26/10/2018 Poulvac E. coli - EMEA/V/C/002007 - IG/0976

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

  • IMMUNOLOGICALS FOR AVES
  • live bacterial vaccines for domestic fowl.

Therapeutic indication

For active immunisation of broiler chickens and future layers / breeders in order to reduce mortality and lesions (pericarditis, perihepatitis, airsacculitis) associated with Escherichia coli serotype O78.

Assessment history

How useful was this page?

Add your rating